TG Therapeutics to Participate in the Jefferies Global Healthcare Conference

Rhea-AI Summary

TG Therapeutics (NASDAQ: TGTX) has announced its participation in the upcoming Jefferies Global Healthcare Conference, taking place at the Marriott Marquis in New York City from June 3-5, 2025. Michael S. Weiss, the company's Chairman and CEO, will engage in a fireside chat scheduled for Wednesday, June 4, 2025, at 12:50 PM ET. Investors and interested parties can access a live webcast of the presentation through the Events page in the Investors & Media section of TG Therapeutics' website.

Fireside chat scheduled for Wednesday, June 4, 2025, at 12:50pm ET

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX) today announced that Michael S. Weiss, the Company’s Chairman and Chief Executive Officer, will participate in the Jefferies Global Healthcare Conference, being held at the Marriott Marquis, in New York City on June 3-5, 2025. The fireside chat is scheduled to take place on Wednesday, June 4, 2025, at 12:50 PM ET.

A live webcast of the fireside chat will be available on the Events page, located within the Investors & Media section, of the Company’s website at http://ir.tgtherapeutics.com/events.

ABOUT TG THERAPEUTICS
TG Therapeutics is a fully integrated, commercial stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. In addition to a research pipeline including several investigational medicines, TG has received U.S. Food and Drug Administration (FDA) approval for BRIUMVI® (ublituximab-xiiy), for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval by the European Commission (EC) and the Medicines and Healthcare Products Regulatory Agency (MHRA) for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features, in Europe and the United Kingdom, respectively. For more information, visit www.tgtherapeutics.com, and follow us on Twitter @TGTherapeutics and on LinkedIn.

BRIUMVI® is a registered trademark of TG Therapeutics, Inc.

CONTACT:

Investor Relations
Email: ir@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 4

Media Relations:
Email: media@tgtxinc.com
Telephone: 1.877.575.TGTX (8489), Option 6

FAQ

When is TG Therapeutics (TGTX) presenting at the Jefferies Global Healthcare Conference 2025?

TG Therapeutics will present on Wednesday, June 4, 2025, at 12:50 PM ET.

Who will represent TG Therapeutics (TGTX) at the Jefferies Healthcare Conference?

Michael S. Weiss, the Company's Chairman and Chief Executive Officer, will represent TG Therapeutics.

Where can I watch TG Therapeutics' (TGTX) presentation at the Jefferies Conference?

The presentation can be viewed via live webcast on TG Therapeutics' website at http://ir.tgtherapeutics.com/events.

Where is the Jefferies Global Healthcare Conference 2025 being held?

The conference is being held at the Marriott Marquis in New York City from June 3-5, 2025.